Literature DB >> 26868332

HOTAIR in relation to epithelial-mesenchymal transition and cancer stem cells in molecular subtypes of endometrial cancer.

Agata Łuczak1, Anna Supernat1, Sylwia Łapińska-Szumczyk2, Daniel Jachimowicz1, Hanna Majewska3, Jacek Gulczyński4, Anna J Żaczek1.   

Abstract

BACKGROUND: Endometrial cancer (EC) is a hormone-related disease, showing highly diverse features of ER/PR/HER2 status-based molecular subtypes. Long noncoding RNA (lncRNA) HOX antisense intergenic RNA (HOTAIR) has recently emerged as a key molecule in many cancers, triggering epithelial-mesenchymal transition (EMT)-mediated cancer stem cell (CSC) formation, but little is known about its significance in EC. Thus, we aimed to investigate the clinical significance of HOTAIR itself in different molecular subtypes of EC and possible links between HOTAIR, EMT and CSC-related markers.
METHODS: The study group included 156 consecutive, stage I-IV EC patients treated between 2000 and 2010. ER, PR and HER2 protein expression were examined by immunohistochemistry (IHC) on tissue microarrays. RT-qPCR was used to analyze the expression levels of HOTAIR, EMT-related genes - SNAIL and SLUG - and the CSCs marker CD133.
RESULTS: Molecular subtypes, defined as ER/PR+HER2+, ER/PR+HER2-, ER-PR-HER2+ and ER-PR-HER2-, occurred in 40.2%, 52.3%, 4.7% and 1.9% of cases, respectively. The expression of HOTAIR did not differ between the subtypes, but high HOTAIR expression correlated with shorter overall survival (p = 0.04) in the entire group. The expression levels of HOTAIR, SNAIL, SLUG and CD133 were similar in defined EC molecular subtypes.
CONCLUSIONS: Our data do not confirm the role of HOTAIR in EMT-mediated CSC formation in EC. Neither does the diversity of EC molecular subtypes influence these processes. But HOTAIR expression could serve as an independent prognostic factor in EC. The clinical importance of the above discoveries requires further studies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26868332     DOI: 10.5301/jbm.5000187

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  7 in total

1.  Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs.

Authors:  Nan Li; Kai Yu; Zhong Lin; Dingyuan Zeng
Journal:  Exp Biol Med (Maywood)       Date:  2021-10-27

2.  Long Noncoding RNA HOTAIR Promotes Endometrial Carcinoma Cell Proliferation by Binding to PTEN via the Activating Phosphatidylinositol 3-Kinase/Akt Signaling Pathway.

Authors:  Xiao-Hui Zhang; Pin Hu; Yang-Qin Xie; Yong-Jun Kang; Min Li
Journal:  Mol Cell Biol       Date:  2019-11-12       Impact factor: 4.272

Review 3.  The regulatory roles of lncRNAs in the process of breast cancer invasion and metastasis.

Authors:  Siying Zhou; Yunjie He; Sujin Yang; Jiahua Hu; Qian Zhang; Wei Chen; Hanzi Xu; Heda Zhang; Shanliang Zhong; Jianhua Zhao; Jinhai Tang
Journal:  Biosci Rep       Date:  2018-09-28       Impact factor: 3.840

4.  HOTAIR as a Prognostic Predictor for Diverse Human Cancers: A Meta- and Bioinformatics Analysis.

Authors:  Halil Ibrahim Toy; Didem Okmen; Panagiota I Kontou; Alexandros G Georgakilas; Athanasia Pavlopoulou
Journal:  Cancers (Basel)       Date:  2019-06-05       Impact factor: 6.639

5.  Long noncoding RNA GAPLINC promotes invasion in colorectal cancer by targeting SNAI2 through binding with PSF and NONO.

Authors:  Peng Yang; Tao Chen; Zipeng Xu; Hua Zhu; Jie Wang; Zhenyu He
Journal:  Oncotarget       Date:  2016-07-05

6.  The contrary functions of lncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells.

Authors:  Jianguang Jia; Dankai Zhan; Jing Li; Zhixiang Li; Hongbo Li; Jun Qian
Journal:  J Cell Mol Med       Date:  2018-10-19       Impact factor: 5.310

7.  lncRNA OIP5-AS1 Suppresses Cell Proliferation and Invasion of Endometrial Cancer by Regulating PTEN/AKT via Sponging miR-200c-3p.

Authors:  Yun Liu; Xiaohui Cai; Yixuan Cai; Yue Chang
Journal:  J Immunol Res       Date:  2021-07-28       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.